Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 19, 2026 11:40 ET | Source: Novo Nordisk A/S

Novo Nordisk A/S: Wegovy® HD (semaglutide 7.2 mg) approved in the US, providing 20.7% mean weight loss

US FDA has approved Wegovy® HD (once-weekly injectable semaglutide 7.2 mg) to reduce excess body weight and maintain weight reduction long-term.
March 16, 2026 05:56 ET | Source: Novo Nordisk A/S

Novo Nordisk A/S - share repurchase programme

Bagsværd, Denmark, 16 March 2026 – On 4 February 2026, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council...
March 09, 2026 06:39 ET | Source: Novo Nordisk A/S

Novo Nordisk A/S - share repurchase programme

Bagsværd, Denmark, 9 March 2026 – On 4 February 2026, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council...
March 02, 2026 10:55 ET | Source: Novo Nordisk A/S

Election of employee representatives to the Board of Directors of Novo Nordisk A/S

Bagsværd, Denmark, 2 March 2026 – The employees in Novo Nordisk A/S have completed the election of employee representatives to the Board of Directors of Novo Nordisk A/S. The following employee...
March 02, 2026 06:22 ET | Source: Novo Nordisk A/S

Novo Nordisk A/S - share repurchase programme

Bagsværd, Denmark, 2 March 2026 – On 4 February 2026, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council...
March 02, 2026 04:00 ET | Source: Novo Nordisk A/S

Novo Nordisk announces more than 400 million euro expansion in its manufacturing facility in Athlone, Ireland

The investment will support the upgrade and retrofit of the existing facility and enhance Novo Nordisk’s capacity to manufacture oral GLP-1s outside the US
February 25, 2026 08:00 ET | Source: Novo Nordisk A/S

Novo Nordisk and Vivtex partner to develop next-generation oral medicines for obesity and diabetes

Novo Nordisk and Vivtex Corp announced partnership to develop next-generation oral biologic medicines for obesity, diabetes + associated comorbidities
February 24, 2026 03:39 ET | Source: Novo Nordisk A/S

Novo Nordisk: Triple agonist UBT251 delivers up to 19.7% mean weight loss after 24 weeks in phase 2 trial in China

The United Laboratories International Holdings Limited and Novo Nordisk today announced topline results from a Chinese phase 2 trial of UBT251
February 23, 2026 07:24 ET | Source: Novo Nordisk A/S

Novo Nordisk A/S - share repurchase programme

Bagsværd, Denmark, 23 February 2026 – On 4 February 2026, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and...
February 23, 2026 04:33 ET | Source: Novo Nordisk A/S

Novo Nordisk A/S: CagriSema demonstrated 23% weight loss in an open-label head-to-head REDEFINE 4 trial in people with obesity, the primary endpoint was not achieved

CagriSema achieved 23% weight loss after 84 weeks of treatmentCagriSema 2.4/2.4 mg did not meet the primary endpoint of showing non-inferiority on weight loss compared to tirzepatide 15 mg at 84...